Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.
about
Safety and efficacy of low intensity shockwave (LISW) treatment in patients with erectile dysfunction.Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.From rapalogs to anti-aging formula.Management of erectile dysfunction in hypertension: Tips and tricks.Enhancing cognition before clinical symptoms of dementia.Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction.Phosphodiesterase 5 inhibitors for erectile dysfunction.Phosphodiesterase type 5 inhibitors for erectile dysfunction.The therapeutic dilemma: how to use tadalafil.A case of acute pulmonary thromboembolism after taking tadalafil.Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidencePDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic DiseaseEfficacy and safety of tadalafil taken as needed for the treatment of erectile dysfunction in Asian men: results of an integrated analysis.Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectivesChronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.PDE5 inhibitors: considerations for preference and long-term adherence.Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.Erectile dysfunction patients are more satisfied with penile prosthesis implantation compared with tadalafil and intracavernosal injection treatments.Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study.The efficacy and safety of tadalafil: an update.A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia.Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction.An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy.Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study.Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia.Losartan improves erectile dysfunction in diabetic patients: a clinical trial.Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient.
P2860
Q30383937-F3BB0A30-4BD0-4D63-A8CD-7F633593DDFCQ33225656-2ED81394-4223-4CDA-94CA-0805F6752BE2Q33829205-9A7A3AFE-A5D9-40CF-8565-6687B2B77C6BQ34251875-88D3F69A-2A48-49B3-8B36-97A19D7D8364Q34708103-CE1B36B7-8617-4224-B8E2-61436D4A24B5Q35827790-19134035-338A-46D7-B75A-FA954538400AQ36024890-1E420114-571E-42C9-BCB2-C70E627EBA37Q36040691-34886850-85D1-4B00-B7B0-AA5DA7C86C06Q36154866-C9E8B014-FB28-4955-B961-5101FADFC4D4Q36206628-8C6DACCC-5F48-4CAE-9C9C-E7FA6F27481EQ36291011-C0576E89-FF55-4704-9837-3B80BD2B19C2Q36381067-F7003E6B-8D29-4194-9D6D-E56E7B9178A2Q36494145-B8C2C1D9-E654-4B99-9DD4-DEDFBCE009A3Q36689825-CFE2DDEE-FC25-4D0B-BDFC-C845003D4507Q37018969-60260202-809B-4ABC-B7D1-9451D8AC453FQ37053929-A41ED2B5-C266-45F7-8876-2F882B2A14EBQ37074999-B90CA52B-7B6E-407D-A546-FC772246E265Q37423713-97CAD68D-26D7-4FD1-87E2-6462AC19B6B9Q38020943-772C35D0-00DF-409D-9A2F-50D2A20CA65BQ38107001-FB744F0A-BB39-4E86-8565-2BF41EF1F804Q38122721-38839F71-9DAB-4122-BF72-6367EAFA6CDAQ38815890-5C53EE68-BAA6-4F02-BB6E-B81C311026D0Q38846229-5AD305A9-3ACA-4F36-964D-379C92AB72D4Q44887089-BC0A4671-3FD2-4A10-AF03-EAE300882D76Q44923967-13E90C2A-AC53-4BFC-BB85-7282C43D73E2Q46611139-D9E21F29-42DE-42FE-9289-9575197A0DA4Q46740992-52F5B01D-A6F1-48D4-B495-0CA61951282EQ46803480-5997C217-C54A-49B8-ACAA-DE36A49BE487Q46984861-A5E1C585-3926-4FD0-B184-1C874A5C6A0EQ48601812-DE0EBB6E-6497-415E-8731-A2180AA96B42Q53124729-0156AF09-DF95-4758-90D2-63B7B64F7514Q54603457-B6380C49-35C1-41CF-900D-F24CC395DCA0
P2860
Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.
@ast
Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.
@en
type
label
Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.
@ast
Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.
@en
prefLabel
Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.
@ast
Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.
@en
P2093
P1433
P1476
Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.
@en
P2093
Jünemann KP
Meuleman E
Montorsi F
Valiquette L
P304
339-44; discussion 344-5
P356
10.1016/J.EURURO.2003.11.010
P407
P577
2004-03-01T00:00:00Z